Factor XI and coagulation. Factor XI inhibitors - antithrombotic perspectives.
| Autor: | Vlădăreanu AM; 1'Carol Davila' University of Medicine and Pharmacy, Department of Hematology, Emergency University Hospital of Bucharest, Romania., Roşca A; 2'Carol Davila' University of Medicine and Pharmacy, Department of Functional Sciences, Division of Physiology, Bucharest, Romania. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Romanian journal of internal medicine = Revue roumaine de medecine interne [Rom J Intern Med] 2023 Dec 28; Vol. 62 (2), pp. 91-100. Date of Electronic Publication: 2023 Dec 28 (Print Publication: 2024). |
| DOI: | 10.2478/rjim-2023-0034 |
| Abstrakt: | Factor XI is a zymogen with an important role in the coagulation cascade. It is activated by FXII, thrombin and or it can be autoactivated. It has a prothrombotic effect after being activated by thrombin, but also through its antifibrinolytic action, stabilizing the formed clot. Hereditary deficiency of FXI causes haemophilia C - a disease manifested by an usually provoked, small to moderate mucosal bleeding. People with severe FXI deficiency have a low risk of thrombotic events. Conversely, increased FXI values have been found to be associated with increased risk of venous thromboembolism and ischemic stroke. Lowering serum FXI levels has become a treatment target for the prevention of thrombotic events. New pharmacological agents - FXI inhibitors - have been investigated in phase II clinical trials, with promising results in terms of efficacy and safety in the prevention of thrombotic events. FXI inhibitors are emerging as new anticoagulant agents with broad indication prospects beyond direct oral anticoagulants and vitamin K antagonists. (© 2023 Ana-Maria Vlădăreanu et al., published by Sciendo.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|